<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 19 May 2021 07:23:25 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>百时美施贵宝15.6亿美元引进的TIGIT双抗是什么</title><link>https://mp.weixin.qq.com/s/EOVcJccTVe4oD5Sob1HMtg</link><description></description><content:encoded><![CDATA[百时美施贵宝15.6亿美元引进的TIGIT双抗是什么]]></content:encoded><pubDate>Wed, 19 May 2021 06:59:21 +0800</pubDate></item><item><title>结构生物学最新技术| MicroED能为共晶结构解析带来什么？</title><link>https://mp.weixin.qq.com/s/jSBnw_aW5ZPJYboN8xYapw</link><description></description><content:encoded><![CDATA[结构生物学最新技术| MicroED能为共晶结构解析带来什么？]]></content:encoded><pubDate>Wed, 19 May 2021 06:59:21 +0800</pubDate></item><item><title>信达生物PD-1美国上市申请获受理</title><link>https://mp.weixin.qq.com/s/cUaAslMF2tbvDeha4YFL0Q</link><description></description><content:encoded><![CDATA[信达生物PD-1美国上市申请获受理]]></content:encoded><pubDate>Tue, 18 May 2021 12:57:02 +0800</pubDate></item><item><title>ProTriTAC技术</title><link>https://mp.weixin.qq.com/s/dVJBn1gORZCcoayiSKc-9Q</link><description></description><content:encoded><![CDATA[ProTriTAC技术]]></content:encoded><pubDate>Tue, 18 May 2021 12:57:02 +0800</pubDate></item><item><title>TRuC-T细胞疗法，配备PD-1/CD28开关</title><link>https://mp.weixin.qq.com/s/6gjwzjVnu8u5sR6h031G0Q</link><description></description><content:encoded><![CDATA[TRuC-T细胞疗法，配备PD-1/CD28开关]]></content:encoded><pubDate>Tue, 18 May 2021 12:57:02 +0800</pubDate></item><item><title>PD-1/HER2：信达生物、三生国健、上海药物所</title><link>https://mp.weixin.qq.com/s/V2jBWgZzCF41hpoupC7Z3g</link><description></description><content:encoded><![CDATA[PD-1/HER2：信达生物、三生国健、上海药物所]]></content:encoded><pubDate>Tue, 18 May 2021 12:57:02 +0800</pubDate></item><item><title>NGM Biopharma技术全梳理</title><link>https://mp.weixin.qq.com/s/VDbmXf8Xjsvy4EvvIbiCAw</link><description></description><content:encoded><![CDATA[NGM Biopharma技术全梳理]]></content:encoded><pubDate>Mon, 17 May 2021 13:50:47 +0800</pubDate></item><item><title>PD-(L)1/TGF-β双抗研发现状分析</title><link>https://mp.weixin.qq.com/s/XyEjrn80c_bKRND0zxVqsg</link><description></description><content:encoded><![CDATA[PD-(L)1/TGF-β双抗研发现状分析]]></content:encoded><pubDate>Mon, 17 May 2021 13:50:47 +0800</pubDate></item><item><title>信念医药申报血友病基因疗法：BBM-H901</title><link>https://mp.weixin.qq.com/s/mMOEuOFoGo8eHP_XtCw__Q</link><description></description><content:encoded><![CDATA[信念医药申报血友病基因疗法：BBM-H901]]></content:encoded><pubDate>Mon, 17 May 2021 13:50:47 +0800</pubDate></item><item><title>肿瘤免疫的“跨界选手”</title><link>https://mp.weixin.qq.com/s/ZcssgH5SmWn-gzKE6Du67g</link><description></description><content:encoded><![CDATA[肿瘤免疫的“跨界选手”]]></content:encoded><pubDate>Sun, 16 May 2021 07:27:30 +0800</pubDate></item><item><title>基因泰克转化医学全景介绍</title><link>https://mp.weixin.qq.com/s/99KyDBAC_U2ip24Z1eQWvg</link><description></description><content:encoded><![CDATA[基因泰克转化医学全景介绍]]></content:encoded><pubDate>Sun, 16 May 2021 07:27:30 +0800</pubDate></item><item><title>FDA批准补体C3环肽抑制剂，疗效完胜Soliris</title><link>https://mp.weixin.qq.com/s/rDYhAL2rBD8XAybnHaFelg</link><description></description><content:encoded><![CDATA[FDA批准补体C3环肽抑制剂，疗效完胜Soliris]]></content:encoded><pubDate>Sat, 15 May 2021 07:44:11 +0800</pubDate></item><item><title>康宁杰瑞技术全梳理</title><link>https://mp.weixin.qq.com/s/vpT3xzLfZDCXKyOgddtr4A</link><description></description><content:encoded><![CDATA[康宁杰瑞技术全梳理]]></content:encoded><pubDate>Fri, 14 May 2021 10:22:22 +0800</pubDate></item><item><title>科望医药技术全梳理</title><link>https://mp.weixin.qq.com/s/UnQRMI2SbfnSsakg5vzdcw</link><description></description><content:encoded><![CDATA[科望医药技术全梳理]]></content:encoded><pubDate>Fri, 14 May 2021 10:22:22 +0800</pubDate></item><item><title>诗健生物申报Trop2 ADC：国内第6家</title><link>https://mp.weixin.qq.com/s/MbTf9wYm-4ameElNQrwJlQ</link><description></description><content:encoded><![CDATA[诗健生物申报Trop2 ADC：国内第6家]]></content:encoded><pubDate>Thu, 13 May 2021 16:09:41 +0800</pubDate></item><item><title>QbD 2021第二届生物药质量科学大会</title><link>https://mp.weixin.qq.com/s/93RLiG-8TcAaOOaAWPLXgg</link><description></description><content:encoded><![CDATA[QbD 2021第二届生物药质量科学大会]]></content:encoded><pubDate>Thu, 13 May 2021 16:09:41 +0800</pubDate></item><item><title>普米斯申报首个三抗：PM8003</title><link>https://mp.weixin.qq.com/s/xi_moWN3B3a167jVav1G1w</link><description></description><content:encoded><![CDATA[普米斯申报首个三抗：PM8003]]></content:encoded><pubDate>Thu, 13 May 2021 16:09:41 +0800</pubDate></item><item><title>SIRPα融合蛋白：IgG1还是IgG4？</title><link>https://mp.weixin.qq.com/s/X0-4FWLPgPmNpljM3iQ9oA</link><description></description><content:encoded><![CDATA[SIRPα融合蛋白：IgG1还是IgG4？]]></content:encoded><pubDate>Wed, 12 May 2021 17:54:56 +0800</pubDate></item><item><title>项目转让：长效偏向性IL-2</title><link>https://mp.weixin.qq.com/s/uSgMzhIPJ2bMOf8coHJmjA</link><description></description><content:encoded><![CDATA[项目转让：长效偏向性IL-2]]></content:encoded><pubDate>Wed, 12 May 2021 17:54:56 +0800</pubDate></item><item><title>首个TSLP抗体申报上市：安进/阿斯利康Tezepelumab</title><link>https://mp.weixin.qq.com/s/qgSwXXoqskJfmSRHsiOA6A</link><description></description><content:encoded><![CDATA[首个TSLP抗体申报上市：安进/阿斯利康Tezepelumab]]></content:encoded><pubDate>Tue, 11 May 2021 09:40:47 +0800</pubDate></item></channel></rss>